TITLE

Fingolimod Associated Bilateral Cystoid Macular Edema--Wait and See?

AUTHOR(S)
Pul, Refik; Osmanovic, Alma; Schmalstieg, Holger; Pielen, Amelie; Pars, Kaweh; Schwenkenbecher, Philipp; Sühs, Kurt Wolfram; Yildiz, Özlem; Frank, Benedikt; Stangel, Martin; Skripuletz, Thomas
PUB. DATE
December 2016
SOURCE
International Journal of Molecular Sciences;Dec2016, Vol. 17 Issue 12, p2106
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing-remitting multiple sclerosis (MS). Several pivotal and real-world studies have demonstrated that fingolimod is associated with the development of macular edema (ME). Herein, we present a case of a diabetic MS patient who developed severe bilateral ME during fingolimod treatment. By means of this case study we provide a detailed review about fingolimod associated macular edema (FAME), its current incidence with or without diabetes mellitus, and previous therapy attempts and outcomes in MS patients. Intravitreal administration of antibodies raised against vascular endothelial growth factor A (VEGF-A) has not yet been used in the management of FAME, however, the excellent therapeutic response in our patient may justify the use of anti-VEGF-A agents in combination with cessation of fingolimod to achieve fast resolution of FAME and to prevent visual deficits, particularly in bilateral FAME.
ACCESSION #
120516930

 

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics